Patients who have given false positive tests include 2 patients with liver disease, 2 probable cases of pluriglandular syndrome, and a patient with a pituitary tumour.
In 3 of the patients with insulinoma there was little change ir the blood glucose concentration during the test yet severe neuroglycopenia developed in 2, and mild neuroglycopenia in 1. The EEG was abnormal in the patient examined.
One of the diagnostic difficulties with insulinoma is that the tumour usually grows slowly-and the symptoms are progressive. The (Reerink et al. 1960) . In progesterone the angle methyl group at C10 is in the P (or cis) position whereas the hydrogen atom attached to Cg is in the oc (or trans) position (Fig IA) .
The corresponding compound (retro-progesterone) in the new series is the 9fl, 10ac stereoisomeric analogue (Fig 1B) .
The 6-dehydro-derivative has been found by Scholer (1960) (Bishop et al. 1961 In planning our studies on the effect of isopregnenone on dysmenorrhoea we therefore presumed that, if successful, it would prevent the pain of the subsequent menstrual bleeding by in--hibiting ovulation. We consequently decided to give the compound daily from day 5 to day 25 of the cycle. Because little was known about the effective strength of the preparation when administered to women the dosage varied between 1 and 30 mg. On analysing the results in a group of 44 dysmenorrhoeic women treated for a total of 85 cycles we found a significant dose-response relationship, the optimal daily dose being 15 mg. 'Break-through' bleeding, that is, bleeding beginning during the course of treatment instead of after its withdrawal occurred in 21 cycles and, although it was painless in 18 and therefore gratified the patients, we eliminated them in calculating our final results (Table 1) .
The results are divided into failures, in which the subsequent period was accompanied by incapacitating pain, and successes, in which the period was either painless or else accompanied by discomfort which, however, was not incapacitating. In fact 35 out of the 47 cycles in this group were completely painless. In order to simplify the presentation of our results I have separated the cycles into two dosage groups only, those in which 10 mg was given daily and those in which 15 mg or more was given. In the first group one patient received 5 mg and in the second 29 received 20 mg, but the success rate was exactly the same whether the daily dose was 15 mg or 20 mg. The overall success rate was 73 %, 63 % on the 10 mg dose and 82 % on the dose of 15 mg or more. Isopregnenone therefore prevents spasmodic dysmenorrhoea in a high percentage of cases when given in 15 mg doses or more from the 5th to 25th day of the cycle. Furthermore in our experience of over 4,500 treatment-days there were no unpleasant side-effects.
Early in our trials we found that isopregnenone It is unwise, however, to rely solely on basal temperature patterns as an indication of whether ovulation has occurred. Diczfalusy and Tillinger therefore estimated the urinary (estrogen and pregnanediol output in 2 successive 28-day cycles in 6 women, not necessarily suffering from dysmenorrhcea. In the first cycle no treatment was given whereas isopregnenone was administered in doses of 10 to 30 mg daily from the 5th to the 25th day in the second cycle. No significant difference was found in the treated and untreated cycles. (It had previously been established that isopregnenone is not excreted as pregnanediol.) These studies also suggest therefore that in these doses isopregnenone does not inhibit ovulation.
Finally Borell-administered isopregnenone in doses up to 40 mg daily from the 5th day onwards to 12 women who were due to be operated upon in the cycle in which the treatment was being given. The ovaries were inspected between the 18th and 23rd day. In 10 cases the presence of a freshly formed corpus luteum was confirmed histologically, whereas in another case a recently ruptured Graafian follicle was identified. In the 12th case a follicular cyst was removed but no luteal tissue was identified. These observations fully support the contention that isopregnenone, in these doses, does not inhibit ovulation.
In the light of these findings it seems that current views concerning the hormonal factors in the causation of spasmodic dysmenorrhoea may need reconsideration.
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